4D Molecular Therapeutics share price logo

4D Molecular Therapeutics

NASDAQ: FDMT

Small Cap

$11.95

+0.58

(+5.10%)

as on

4D Molecular Therapeutics Stock Performance

as on November 4, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $11.46
    $12.09
    downward going graph

    4.10%

    Downside

    1.17%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $6.96
    $16.93
    downward going graph

    41.76%

    Downside

    41.67%

    Upside

    downward going graph

4D Molecular Therapeutics share price movements today

Previous Close
$11.37
Open
$11.46
Volume
741.1K
Market Cap
$657.4M
Day's Low - High
$11.46 - $12.09
52 Week Low - High
$6.96 - $16.93

4D Molecular Therapeutics Historical Returns

1 Month Return
-16.83 %
3 Month Return
+ 12.69 %
1 Year Return
+ 1.34 %
3 Year Return
-1.98 %
5 Year Return
-54.67 %

4D Molecular Therapeutics Stock Fundamentals & Key Indicators

Check 4D Molecular Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$657.4M

EPS (TTM)

-2.72

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-4.38

Industry PE ratio

-7.24

PEG Ratio

-0.30

EBITDA

-184.0M

Revenue (TTM)

92.0M

Profit Margin

42.00%

Return On Equity TTM

-41.33%

4D Molecular Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of 4D Molecular Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
StrongBuy$657.4M-54.67%-4.3842.00%0.00%
Neutral$88.5B-36.16%-27.78-12.57%0.00%
StrongBuy$141.7B192.56%32.2786.04%0.00%
Buy$95.5B47.41%19.7685.77%0.40%

Stock Returns calculator for 4D Molecular Therapeutics Stock including INR - Dollar returns

The 4D Molecular Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

4D Molecular Therapeutics investment value today

Current value as on today

₹1,13,729

Returns

₹13,729

(+13.73%)

Returns from 4D Molecular Therapeutics Stock

₹6,506 (+6.51%)

Dollar Impact

₹7,222 (+7.22%)

Analyst Recommendation on 4D Molecular Therapeutics Stock

Based on 4 analysts

BUY

75.00%

Buy

25.00%

Hold

0.00%

Sell

Based on 4 analysts, 75% of analysts recommend a 'BUY' rating for 4D Molecular Therapeutics. Average target price of $28.09

4D Molecular Therapeutics Share Price Target

Get share price movements and forecasts by analysts on 4D Molecular Therapeutics.

What analysts predicted

57.46%UPSIDE

Target Price

$28.09

Current Price

$11.95

Analyzed by

4 Analysts

High

$36

Target

$28.09

Low

$20

4D Molecular Therapeutics target price $28.09, a slight upside of 57.46% compared to current price of $11.95. According to 4 analysts rating.

Indian Investors' Interest in 4D Molecular Therapeutics Stock

Search interest for 4D Molecular Therapeutics Stock has decreased by -57% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-57% versus previous 30 day period

4D Molecular Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
0
0
0
0
0
0
0
85
3
3
Gross Profit
-27
-31
-38
-1
-40
-47
-47
83
0
1
Operating Income
-38
-42
-51
-56
-53
-59
-61
14
-73
-77
EBITDA
-30
-33
-42
-47
-46
-52
-54
12
-66
-74
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
1
1
1
1
1
1
2
1
2
2
Income Before Tax
-32
-34
-43
-49
-47
-54
-56
19
-68
-72
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-32
-34
-43
-49
-47
-54
-56
19
-68
-72
Net Profit Margin
-99435.71%
-637100.00%
100.00%
-178300.00%
-290607.14%
-319573.33%
-52386.67%
97.67%
32.56%
44.75%

4D Molecular Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
5
14
6
13
18
3
20
0
85
Gross Profit
-7
-4
-31
-39
-43
-77
-76
-141
77
Operating Income
-11
-10
-50
-56
-71
-110
-112
-187
-159
EBITDA
-10
-9
-44
-55
-68
-103
-95
-154
-132
Interest Expense
-
-
-
-
-
-
-
-
-
Depreciation
0
0
1
1
3
3
5
6
7
Income Before Tax
-11
-9
-49
-56
-71
-107
-100
-160
-140
Income Tax Expense
0
-
-
-
-
-
-
-
-
Net Income
-11
-9
-49
-56
-71
-107
-100
-160
-140
Net Profit Margin
-134.42%
-29.95%
-454.22%
-289.64%
-240.17%
-2464.81%
-368.54%
-381789.19%
91.05%

4D Molecular Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-32
-34
-43
-49
-47
-54
-56
19
-68
-72
Operating Cash Flow
-29
-30
-29
-45
-47
-43
-46
28
-68
-69
Investing Cash Flow
-263
-73
27
7
31
-13
17
-128
68
25
Financing Cash Flow
318
17
0
0
-
0
0
111
11
42
Change in Cash
26
-86
-1
-38
-15
-63
-28
11
12
-2

4D Molecular Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-11
-9
-49
-56
-71
-107
-100
-160
-140
Operating Cash Flow
8
-16
-36
-50
-69
-86
-75
-134
-109
Investing Cash Flow
7
0
-3
-1
-172
-17
115
-302
-92
Financing Cash Flow
0
84
-2
278
118
3
156
337
112
Change in Cash
15
67
-42
227
-123
-100
196
-99
-89

Global Institutional Holdings in 4D Molecular Therapeutics

Check out the Institutions with significant holdings in 4D Molecular Therapeutics.

Funds
Holdings
Peter Kolchinsky
9.14%
BlackRock, Inc.
8.23%
Vanguard
4.73%
iShares
4.17%
VANGUARD INDEX FUNDS
3.71%

4D Molecular Therapeutics News & Key Events

  • img

    Today's Timeline - 28 September

    Mon, 06:02 PM

    -

    4D Molecular Therapeutics enrolls first patients in 4SIGHT Phase 3 trial for diabetic macular edema treatment.

Insights on 4D Molecular Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 3.04M → 3.78M (in $), with an average increase of 19.4% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Moderna, Inc. Common Stock has given 184.8% return, outperforming this stock by 186.8%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 829.8% return, outperforming this stock by 824.0%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 3 quarters, 19.39M → -72.93M (in $), with an average decrease of 230.3% per quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, FDMT stock has moved down by -12.1%

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.
Organisation4D Molecular Therapeutics
Headquarters5858 Horton Street, EmeryVille, CA, 94608, US
IndustryBiotechnology
CEODavid H. Kirn

Key Management of 4D Molecular Therapeutics

Name

Title

Mr. Kristian Humer M.B.A.

CFO and Principal Financial & Accounting Officer

Dr. Fariborz Kamal Ph.D.

Chief Technical Advisor

Ms. Theresa Janke

Co-Founder & Chief of Staff

Dr. Katy Barglow Ph.D.

Chief Technical Officer

Dr. Noriyuki Kasahara M.D., Ph.D.

Chief Scientific Advisor

Dr. John F. Milligan Ph.D.

Executive Chairman

Julian Pei

Head of Investor Relations & Corporate Finance

Dr. Scott P. Bizily J.D., Ph.D.

Chief Legal Officer & Corporate Secretary

Dr. An Song Ph.D.

Chief Translational Medicine Advisor

Dr. David H. Kirn M.D.

Co-Founder, President, CEO & Director

FAQs

What is 4D Molecular Therapeutics share price today?

4D Molecular Therapeutics share price today is $11.95 as on at the close of the market. 4D Molecular Therapeutics share today touched a day high of $12.09 and a low of $11.46.

What is the 52 week high and 52 week low for 4D Molecular Therapeutics share?

4D Molecular Therapeutics share touched a 52 week high of $16.93 on and a 52 week low of $6.96 on . 4D Molecular Therapeutics stock price today i.e. is closed at $11.95,which is 29.42% down from its 52 week high and 71.70% up from its 52 week low.

What is 4D Molecular Therapeutics's market capitalisation today?

4D Molecular Therapeutics market capitalisation is $0.00T as on .

How to invest in 4D Molecular Therapeutics Stock (FDMT) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for 4D Molecular Therapeutics on INDmoney app. Click on Buy button.

What is the minimum amount required to buy 4D Molecular Therapeutics Stock (FDMT) from India?

Indian investors can start investing in 4D Molecular Therapeutics (FDMT) shares with as little as ₹94.73999786376953 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹947.40 in 4D Molecular Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on 4D Molecular Therapeutics share’s latest price of $11.95 as on November 4, 2026 at 8:45 am IST, you will get 0.8368 shares of 4D Molecular Therapeutics. Learn more about fractional shares .

What are the returns that 4D Molecular Therapeutics has given to Indian investors in the last 5 years?

4D Molecular Therapeutics stock has given -54.67% share price returns and 27.47% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?